Specialised Adult whole-body MRI (WBMRI) Surveillance for Cancer Predisposing Syndromes

The key objective of this procurement is to commission Specialised Adult whole-body MRI (WBMRI) Surveillance for Cancer Predisposing Syndromes. Services will be commissioned across seven (7) geographical regions to serve the population of England, as outlined below:<br/><br/>Lot 1: London<br/>Lot 2: East of England<br/>Lot 3: South East<br/>Lot 4: South West<br/>Lot 5: Midlands <br/>Lot 6: North East and Yorkshire<br/>Lot 7: North West<br/><br/>Bidders are to note:<br/>- There is no restriction on the number of sites that may be commissioned.<br/>- Providers must be located in and deliver services from the defined geographical area(s) that they are interested in providing services to.<br/><br/>Link to NHS England Regions:<br/>NHS England " Regional teams (https://www.england.nhs.uk/about/regional-area-teams/). <br/><br/>Inherited cancer predisposition syndromes are genetic conditions that increase the risk of developing one or more types of cancer. Scanning will be commissioned for three rare inherited cancer predisposition syndromes; Li-Fraumeni syndrome (LFS), constitutional mismatch repair deficiency syndrome (CMMRD) and rhabdoid tumour predisposition syndrome (RTPS). <br/><br/>Published clinical guidelines for these conditions recommend the use of regular whole-body MRI (WBMRI) with the aim of detecting cancers at an early stage. The provision of expanded capacity for WBMRI scanning aims to improve clinical care of individuals once an inherited cancer predisposition has been diagnosed.<br/><br/>Providers will:<br/>* Provide, interpret and report WB-MRI Scanning for the patient cohort described.<br/>* Provide, interpret, and report brain MRI Scanning (the first one with contrast when possible).<br/>* Establish effective pathways (including sharing results) with providers.<br/>* Be linked to regional genetic centres to allow continuity of care.<br/>* Facilitate communication with referrers including consultant clinical geneticists<br/>* Have capacity to plan and undertake WBMRI under general anaesthetic if re-quired.<br/>* Have information governance processes that permit sharing clinical and imaging data across organisations involved with providing a cancer surveillance service, and collection of clinical outcome and monitoring data.<br/>* Engage positively with associated patient support groups. <br/>* Ensure clear communication with Genetics Services and patients, to support patients to make decisions on where to access screening.<br/>* Work collaboratively with other organisations e.g. within imaging networks, to provide scanning and reporting capacity and expertise to meet the needs of their population including transition between paediatric and adult services.<br/>* Operate Quality Assessment processes according to CQC standards<br/>* Screening will be in addition to breast screening undertaken through the National VHRS Programme<br/>* Provide facilities will be in line with NHS guidance on Facilities for diagnostic imaging and interventional radiology.<br/>* Support continued educational initiatives for non-genetics healthcare professionals to improve expertise and understanding of cancer predisposition syndromes.<br/>* Liaise with partners across cancer alliances to support early diagnosis innovation opportunities<br/>* Ensure screening frequency will be in accordance with surveillance protocols.<br/><br/>Providers must be able to meet the requirements set out in this Competitive Process and deliver the contract in accordance with its terms.<br/><br/>To express interest and participate in the Competitive Process, please register and apply via Atamis e-sourcing portal https://health-family.force.com/s/Welcome Should Tenderers have any queries, or problems using the portal, they should contact the Helpdesk at:<br/><br/>Phone: 08000988201<br/>E-mail: support-health@atamis.co.uk<br/><br/>The closing date for completed Competitive Process responses is 12:00pm (noon), on Monday 8 December 2025.<br/><br/>Atamis Project reference C310713.<br/><br/>The contract duration is for three (3) years with the Commissioners having the option to extend for up to an additional two (2) year(s) (maximum contract duration five (5) years).<br/><br/>This is a Provider Selection Regime (PSR) Contract Notice. The awarding of this contract is subject to<br/>the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 do not apply.